Xera Med Research is a private research lab in Boca Raton (with a satellite location in Fort Lauderdale) who services Pharma and Diagnostics Research & Development efforts. We are an FDA regulated and IRB approved research facility established in 2015. Our main objective in offering testing is to identify COVID-19 positive patients to donate plasma or blood for clinical research purposes.

SARS-CoV-2 is the virus that has been named COVID-19. Coronavirus (COVID-19) is an illness caused by a virus that can spread from person to person. For more information on COVID-19 and how to help slow the spread, visit www.cdc.gov

For starters, knowing that you have COVID-19 antibodies tells you that you have had the virus and your immune system was able to handle the virus, possibly without you even noticing any symptoms.

We are a private research lab, not a government testing site nor a hospital. We provide our own staffing, PPE, lab supplies, and other resources to administer the tests. We are offering testing to the public at various price points depending on various factors. Please refer to our booking page for list of tests and pricing. At this time we do not accept medical insurance, but are able to issue you a receipt for you to submit to your carrier for reimursement.

The COVID-19 PCR test (nose swab) collects physical pieces of coronavirus from the back of the nose where it meets the throat. THis test can detect if you currently have an active COVID-19 in your system. A positive result indicates that viral genetic material is present. A negative result indicates that the SARS-CoV2 virus that causes the COVID-19 disease was not found. It is possible to have a very low level of the virus in the body with a negative test result. The COVID-19 ANTIBODIES test (blood draw) is designed to detect antibodies (immunoglobulins, IgG and IgM) against the coronavirus that causes the disease called COVID-19. Antibodies are proteins produced by the immune system in response to an infection and are specific to that particular infection.

COVID-19 PCR test is a nose swab test performed by collecting physical pieces of virus from the back of the nose. This test can detect if you currently have an active COVID-19 virus in your system.

Xera Med Research performs venipuncture blood draw to obtain blood for the antibody test. We collect 3-4 vials of blood, all in a single draw. This is very similar to going to your doctor for routine blood tests. We use some of the vials to perform the antibodies tests and the other ones are used for research.

COVID-19 PCR test (swab) standard turnaround time is 3-5 busienss days. COVID-19 PCR test (swab) HOT RUSH turnaround time is next day. COVID-19 ANTIBODIES test (blood work) is approximately 5 business days.

Your test results are confidential and protected by HIPAA. We will call you with your results. If you require physical document showing your test result, let us know and we will email it to you.

Xera Med Research services adults 18 years old and up.

Xera Med Research only uses the most reliable InBios for the ELISA test which has the FDA Emergency Use Authorization (EUA). There are several tests that received FDA EUA (such as Epitope’s kit NOT used by Xera) that have their EUA revoked for discrepancies in testing. Please keep this in mind should you choose to get tested at another lab. For more information on these tests and their manufacturers, please review their websites. The tests used by Xera Med Research are most sensitive and have shown to be most reliable.

Xera Med Research uses the most reliable and sensitive tests available with accuracy rate of 99.8%. We do not make the test and we put our trust in the FDA’s review and guidelines for EUA. It is known globally that there are discrepancies even with FDA EUA tests – used by other laboratories and the sensitivity of the test can vary. Regardless, we are required to report all results to the DOH.

ELISA, enzyme-linked immunosorbent assay, is an analytical biochemistry assay. The assay uses a solid-phase enzyme immunoassay (EIA) to detect the presence of a ligand (commonly a protein) in a liquid sample using antibodies directed against the protein to be measured. ELISA has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries.

The name of the virus is in fact SARS-CoC2 which is the same as COVID-19. Your lab report with show if you have either the IgM or IgG antibodies or both. For more virology information please contact your healthcare provider.

Antibody tests, a type of serological test, detect antibodies present in the blood when the body is responding to or has responded to a specific infection, such as COVID-19. Antibody tests detect the body’s immune response to the infection caused by the virus rather than detecting the virus itself.

Our test method platforms have received FDA Emergency Use Authorization (EUA). EUA does not mean FDA “approved” – FDA approval requires years of research, validation and numerous clinical trials.

Testing individuals may help identify who has developed antibodies against SARS-CoV-2. The result of ongoing research are needed before it is know whether these antibodies are associated with protection from future infection. Current results can help inform who may qualify to donate blood that can be used to manufacture convalescent plasma, an investigational product for use with those who are seriously ill from COVID-19. The results can help determine how widely the virus has spread in our communities. You can read more on the importance of antibody testing in addressing COVID-19 here: https://discoverysedge.mayo.edu/2020/04/03/the-importance-of-antibody-testing-in-addressing-covid-19/

For one, a serologic test can reveal whether a person might have developed immunity to COVID-19. Researchers haven't determined yet whether a person who has had and recovered from COVID-19 is protected from getting it again. But anecdotal evidence from China; preliminary studies in animal models; and experience from previous outbreaks, like severe acute respiratory syndrome and Middle East respiratory syndrome, suggest this might be the case. Having a serologic test may provide the opportunity to tell, for example, whether health care workers have developed immunity. Although such health care workers would still be required to wear personal protective equipment, they would be at lower risk for getting re-infected, compared to health care workers who do not have this immunity. A serologic test also might be used to determine the levels of COVID-19-related antibodies in a person's blood ― information that may be useful in the experimental treatment known as convalescent plasma therapy. Plasma is the component of the blood with no blood cells. The idea behind this treatment, which involves giving patients an infusion of antibody-rich plasma from those who have recently recovered, is that COVID-19 antibodies might neutralize the virus or jump-start a patient's own immune response. Researchers studying COVID-19 in China have suggested in two small case studies of patients that this pre-antibiotic era approach to treating infectious diseases might be a useful tactic in the pandemic. But studies of previous coronaviruses suggest that donors need to have high levels of antibodies in their blood for the therapy to work.

Xera Med Research is a private research lab in Boca Raton (with a satellite location in Fort Lauderdale) who services Pharma and Diagnostics Research & Development efforts. We are an FDA regulated and IRB approved research facility established in 2015. Our main objective in offering testing is to identify COVID-19 positive patients to donate plasma or blood for clinical research purposes.

SARS-CoV-2 is the virus that has been named COVID-19. Coronavirus (COVID-19) is an illness caused by a virus that can spread from person to person. For more information on COVID-19 and how to help slow the spread, visit www.cdc.gov

For starters, knowing that you have COVID-19 antibodies tells you that you have had the virus and your immune system was able to handle the virus, possibly without you even noticing any symptoms.

We are a private research lab, not a government testing site nor a hospital. We provide our own staffing, PPE, lab supplies, and other resources to administer the tests. We are offering testing to the public at various price points depending on various factors. Please refer to our booking page for list of tests and pricing. At this time we do not accept medical insurance, but are able to issue you a receipt for you to submit to your carrier for reimursement.

The COVID-19 PCR test (nose swab) collects physical pieces of coronavirus from the back of the nose where it meets the throat. THis test can detect if you currently have an active COVID-19 in your system. A positive result indicates that viral genetic material is present. A negative result indicates that the SARS-CoV2 virus that causes the COVID-19 disease was not found. It is possible to have a very low level of the virus in the body with a negative test result. The COVID-19 ANTIBODIES test (blood draw) is designed to detect antibodies (immunoglobulins, IgG and IgM) against the coronavirus that causes the disease called COVID-19. Antibodies are proteins produced by the immune system in response to an infection and are specific to that particular infection.

COVID-19 PCR test is a nose swab test performed by collecting physical pieces of virus from the back of the nose. This test can detect if you currently have an active COVID-19 virus in your system.

Xera Med Research performs venipuncture blood draw to obtain blood for the antibody test. We collect 3-4 vials of blood, all in a single draw. This is very similar to going to your doctor for routine blood tests. We use some of the vials to perform the antibodies tests and the other ones are used for research.

COVID-19 PCR test (swab) standard turnaround time is 3-5 busienss days. COVID-19 PCR test (swab) HOT RUSH turnaround time is next day. COVID-19 ANTIBODIES test (blood work) is approximately 5 business days.

Your test results are confidential and protected by HIPAA. We will call you with your results. If you require physical document showing your test result, let us know and we will email it to you.

Xera Med Research services adults 18 years old and up.

Xera Med Research only uses the most reliable InBios for the ELISA test which has the FDA Emergency Use Authorization (EUA). There are several tests that received FDA EUA (such as Epitope’s kit NOT used by Xera) that have their EUA revoked for discrepancies in testing. Please keep this in mind should you choose to get tested at another lab. For more information on these tests and their manufacturers, please review their websites. The tests used by Xera Med Research are most sensitive and have shown to be most reliable.

Xera Med Research uses the most reliable and sensitive tests available with accuracy rate of 99.8%. We do not make the test and we put our trust in the FDA’s review and guidelines for EUA. It is known globally that there are discrepancies even with FDA EUA tests – used by other laboratories and the sensitivity of the test can vary. Regardless, we are required to report all results to the DOH.

ELISA, enzyme-linked immunosorbent assay, is an analytical biochemistry assay. The assay uses a solid-phase enzyme immunoassay (EIA) to detect the presence of a ligand (commonly a protein) in a liquid sample using antibodies directed against the protein to be measured. ELISA has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries.

The name of the virus is in fact SARS-CoC2 which is the same as COVID-19. Your lab report with show if you have either the IgM or IgG antibodies or both. For more virology information please contact your healthcare provider.

Antibody tests, a type of serological test, detect antibodies present in the blood when the body is responding to or has responded to a specific infection, such as COVID-19. Antibody tests detect the body’s immune response to the infection caused by the virus rather than detecting the virus itself.

Our test method platforms have received FDA Emergency Use Authorization (EUA). EUA does not mean FDA “approved” – FDA approval requires years of research, validation and numerous clinical trials.

Testing individuals may help identify who has developed antibodies against SARS-CoV-2. The result of ongoing research are needed before it is know whether these antibodies are associated with protection from future infection. Current results can help inform who may qualify to donate blood that can be used to manufacture convalescent plasma, an investigational product for use with those who are seriously ill from COVID-19. The results can help determine how widely the virus has spread in our communities. You can read more on the importance of antibody testing in addressing COVID-19 here: https://discoverysedge.mayo.edu/2020/04/03/the-importance-of-antibody-testing-in-addressing-covid-19/

For one, a serologic test can reveal whether a person might have developed immunity to COVID-19. Researchers haven't determined yet whether a person who has had and recovered from COVID-19 is protected from getting it again. But anecdotal evidence from China; preliminary studies in animal models; and experience from previous outbreaks, like severe acute respiratory syndrome and Middle East respiratory syndrome, suggest this might be the case. Having a serologic test may provide the opportunity to tell, for example, whether health care workers have developed immunity. Although such health care workers would still be required to wear personal protective equipment, they would be at lower risk for getting re-infected, compared to health care workers who do not have this immunity. A serologic test also might be used to determine the levels of COVID-19-related antibodies in a person's blood ― information that may be useful in the experimental treatment known as convalescent plasma therapy. Plasma is the component of the blood with no blood cells. The idea behind this treatment, which involves giving patients an infusion of antibody-rich plasma from those who have recently recovered, is that COVID-19 antibodies might neutralize the virus or jump-start a patient's own immune response. Researchers studying COVID-19 in China have suggested in two small case studies of patients that this pre-antibiotic era approach to treating infectious diseases might be a useful tactic in the pandemic. But studies of previous coronaviruses suggest that donors need to have high levels of antibodies in their blood for the therapy to work.